The life science industry is shifting gears, widening the gap in the race for next-generation solutions. This facility-focused report will help you get (and stay) ahead.
Read MoreNoel Maestre, PE, LEED AP
Vice President, Life Sciences
San Diego, CA
Noel Maestre is the Vice President of life sciences, focusing on strategy and evaluating market trends for CRB’s global life science practice. He has an extensive background in team leadership and engineering, specializing in facility planning through operation across traditional and advanced modalities.
Noel comes from an extensive background in mechanical and process utilities engineering with nearly 20 years of experience in the life science industry. He specializes in the design, construction and startup of biotechnology, pharmaceutical and advanced technology facilities, and has emerged as a cell and gene therapy SME. He is experienced in traditional biotechnology/pharmaceutical facility design, including a concentration on single-use process systems, batch versus continuous process and emerging technologies, such as cell and gene therapy. Noel is a graduate of Pennsylvania State University with a Bachelor of Science in mechanical engineering.
“I am extremely passionate about the life-saving promises of ATMP’s curative therapies and bringing them to market in record time.”
Insights By Noel
Life science trends: The price of life saving medicine
This report, the fourth in our Horizons: Life Sciences series, tests this vision of improved patient access. We draw on the perspective of more than 500 small, medium and large companies operating across North America and Europe to examine each submarket in detail, looking closely at the milestones that brought them to this moment and the trends that are shaping their future—trends that will determine how quickly the next revolution in life-changing medicine will unfold.
Read MoreWhat’s next for the life science industry?
Real talk from the front lines of today’s research and manufacturing landscape
Read MoreThe dynamic future of life-saving medicine
Changing the way therapies work, and the changing work of making therapies.
Read MoreDesigning multimodal GMP suites
Considerations for dedicated and campaigned use
Read More